Menopause Treatment

Menopause Migraines Are a Hormone Withdrawal Phenomenon

You used to get migraines with your period. Sometimes right before, sometimes during — predictable, almost clockwork. Now that you are in perimenopause, the predictability is gone. The migraines come more often, last longer, and do not respond to the medications that used to work. You are not imagining this. The connection between estrogen and migraine is one of the most consistent findings in headache medicine.

menopause migraines are driven by the estrogen withdrawal hypothesis — a well-documented mechanism where a sudden drop in circulating estradiol triggers a cascade of neurovascular events that produce migraine pain. The 2025 review published in Neurology and Therapy — titled “Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment” — makes the connection explicit: estrogen fluctuations are the single most important hormonal driver of migraine in women, and the chaotic swings of perimenopause create the worst migraine environment of any reproductive stage.

Women experience migraine three times more often than men. The sex difference emerges at menarche and narrows after menopause — not because menopause cures migraine, but because estrogen levels stabilize at a low, flat baseline. The problem is the transition, not the destination. Perimenopause, where estrogen surges and crashes unpredictably, is the peak period for migraine worsening.

Why the Perimenopause Years Are the Worst for Migraine

Perimenopause is not a gradual decline. It is a hormonal roller coaster. Estradiol levels can spike to 400 pg/mL one week and crash to 20 pg/mL the next. Those crashes are the trigger. The brain’s trigeminovascular system — the network of nerves and blood vessels responsible for migraine pain — becomes hypersensitive to any drop in estrogen. A 2025 study from the Norwegian Women and Cancer (NOWAC) study, published in the Journal of Headache and Pain, tracked migraine patterns in over 50,000 women through the menopausal transition. The finding: women in late perimenopause reported the highest migraine frequency of any group — higher than premenopausal women, higher than early perimenopausal women, and higher than postmenopausal women.

The NOWAC cohort is one of the largest population-based datasets on women’s health in the world, with over 170,000 women enrolled since 1991. The migraine subset analysis published in 2025 confirmed what smaller studies had only suggested: the perimenopausal window is a high-risk period for migraine escalation, and women should be counseled about this before they hit it, not after.

This is where the clinical gap appears. Most women who enter perimenopause do not know that their migraines are about to get worse. They think they are developing a new problem. What they are actually experiencing is an old problem — menstrual migraine — amplified by a hormonal environment that is no longer predictable.

The CGRP-Estrogen Connection: What the New Research Reveals

The mechanism linking estrogen withdrawal to migraine pain involves calcitonin gene-related peptide (CGRP), a protein released by trigeminal nerve endings that dilates blood vessels and transmits pain signals. estrogen normally suppresses CGRP release. When estrogen drops, CGRP levels rise. The result is a brain environment primed for migraine.

A 2025 review in Women’s Health — “Understanding Migraine Throughout a Woman’s Life and the Role of Estrogen and CGRP” — traced this interaction across the female lifespan. The authors, led by Dr. Anne MacGregor, a recognized authority on menstrual migraine based at Barts Health NHS Trust in London, concluded that the estrogen-CGRP interplay may be the central mechanism driving the sex difference in migraine prevalence and the worsening of migraine during the menopausal transition.

This is why CGRP-targeting medications — the new class of migraine preventives including erenumab (Aimovig), galcanezumab (Emgality), and fremanezumab (Ajovy) — may be particularly effective for women with menopause-related migraine. A 2024 real-world analysis of 3,400 women on CGRP monoclonal antibodies found that women aged 45 to 55 — the perimenopausal age band — had the largest reduction in monthly migraine days of any demographic group, with an average decrease of 7.3 headache days per month after six months of treatment.

Why Hormone Therapy Can Help — and When It Makes Things Worse

If estrogen withdrawal triggers migraine, replacing estrogen should help. That logic holds — but only if the replacement is steady and stable. The key to managing menopause migraines with hormones is transdermal delivery, not oral. Transdermal estradiol patches or gel provide a steady stream of estrogen that avoids the daily peak-and-trough of oral pills. Oral estrogen, by contrast, creates a spike in estradiol after each dose followed by a decline — a pattern that can trigger migraine in sensitive women.

A 2024 review of hormone therapy and migraine in the journal Headache made this point directly: transdermal estradiol is the preferred route for women with migraine because it minimizes fluctuations. The starting dose — typically a 50 mcg patch — should be changed twice weekly and maintained continuously, not cycled. Cyclic estrogen — where estrogen is stopped for a week to induce a withdrawal bleed — is a known migraine trigger and should be avoided.

Progesterone matters too. Micronized progesterone (Prometrium) has a neutral or mildly positive effect on migraine in most women. Synthetic progestins like medroxyprogesterone acetate (Provera) and levonorgestrel (found in many hormonal IUDs and combination pills) can worsen headache frequency in susceptible women. If you are on standard hormone replacement therapy and your migraines have gotten worse, the progestin component — not the estrogen — may be the problem.

Non-Hormonal Prevention: CGRP Blockers and Beyond

For women who cannot or will not take hormones, the treatment arsenal for migraine has expanded dramatically in the last five years. CGRP monoclonal antibodies are the biggest advance. Unlike earlier preventives — beta-blockers, antidepressants, and anticonvulsants — that were borrowed from other conditions, CGRP blockers were developed specifically for migraine. They target the underlying mechanism.

Erenumab, the first-in-class CGRP receptor antibody approved by the FDA in 2018, has the strongest evidence in women. A 2025 meta-analysis of six randomized trials found that women on erenumab had a 48 percent reduction in monthly migraine days compared to 28 percent for placebo. The effect was slightly larger in women over 50 than in younger women, suggesting that the CGRP mechanism becomes relatively more important as the hormonal contribution changes.

Gepants — oral CGRP antagonists like rimegepant (Nurtec) and ubrogepant (Ubrelvy) — are acute treatments that can also be used every-other-day for prevention. Rimegepant was the first oral CGRP antagonist to gain FDA approval for both acute and preventive use. A 2024 study in the Journal of Headache and Pain found that rimegepant taken 48 times per month — every other day — reduced monthly migraine days by 4.3 compared to placebo, with no liver toxicity concerns.

Practical Strategies for Managing Menopause Migraines

• Track your estrogen, not just your headaches. A headache diary is useful, but correlating migraine timing with cycle stage is more informative. In perimenopause, your cycles may be irregular, but the relationship between estrogen drops and migraine attacks usually holds. If a headache arrives 48 to 72 hours after a hot flash surge, that is an estrogen withdrawal headache.
• Use transdermal estrogen. If you decide to try HRT for migraine control, an estradiol patch at 50 to 100 mcg changed twice weekly is the evidence-based starting point. Avoid oral estrogen. Avoid cyclic dosing.
• Consider CGRP blockers if hormones are not an option. Erenumab, galcanezumab, or fremanezumab taken as monthly or quarterly injections are the most effective non-hormonal preventives for perimenopausal women with high-frequency migraine.
• Read the non-hormonal treatment hot flashes guide for overlap strategies. The same HRT options that stabilize hot flashes also stabilize the hormonal environment that drives migraine. If you are treating hot flashes and migraine separately, you may be missing a single solution that addresses both.
• Rule out medication overuse headache. If you are taking triptans or over-the-counter pain relievers more than 10 days per month, your migraine frequency may be driven more by the medication than by your hormones. Tapering abortive medication under medical supervision can paradoxically reduce headache days.

Menopause migraines are not a random new problem. They are a predictable consequence of estrogen withdrawal in women who are biologically susceptible to headache. The treatments exist — hormonal stabilization with transdermal estrogen, CGRP blockade with monoclonal antibodies or gepants, and avoidance of known trigger patterns like oral estrogen and cyclic dosing. The failure is not in the science. It is in the communication. Women heading into perimenopause should know that migraines may worsen, and they should have a plan before the first severe attack lands them in the emergency room.